ALX Oncology Stock Plunges 11% After Earnings — Its Quarterly Loss Narrows
The shares were on pace for their third drop of 10% or more this month, with breast-cancer results expected in 2027.
ALX Oncology Holdings, which develops cancer therapies, reversed an initial gain and plunged 11% in Monday trading after its quarterly results. The decline erased $17 million in market value even though its quarterly net loss narrowed.
A Smaller Loss, A Steeper Slide
ALXO shares fell 11.4% to $0.92 in Monday trading, as of 11:17 AM ET. The company’s total market value was about $127.2 million in Monday trading, and the stock was on pace for its third drop of 10% or more this month.
ALX Oncology reported a third-quarter net loss of $21.8 million, smaller than the $22.1 million loss a year earlier.
The shares entered Monday down 8% for the year through Friday’s close, while the S&P 500 had gained 11%. Before Monday’s session, the stock was 60% below its highest closing price of the past year.
Breast-Cancer Readout Moves Into 2027
The second half of 2027 is the expected timing for breast-cancer results from approximately 120 patients, according to Monday’s company update. Chief Executive Officer Jason Lettmann said enrollment “remains robust” in his trial update.
The study tests evorpacept with other cancer drugs in a mid-stage trial for metastatic HER2-positive breast cancer. Evorpacept blocks CD47, a protein that helps cancer cells evade immune-cell attacks.
Results published in September showed higher response rates with evorpacept than with the control treatment in stomach and gastroesophageal junction cancers. ALX Oncology said those findings support further development of the drug in breast cancer.
ALX2004 Results Expected In December
ALX Oncology expects safety and preliminary effectiveness results from its early-stage ALX2004 trial in December. It plans an expert webinar to discuss the findings.
ALX2004 is an antibody-drug combination targeting EGFR, a protein on some tumors. It entered an early-stage trial in August 2025.
The company’s annual report for 2025 described two candidates in clinical trials and no products approved for sale. Approximately 800 subjects had received evorpacept with other cancer treatments to date. Jazz Pharmaceuticals and Sanofi work with ALX Oncology by sponsoring trials that combine evorpacept with their own drugs.
The company expects the second half of 2027 to bring the breast-cancer results, making December’s planned ALX2004 readout the nearer clinical milestone.
Sources
- EX-99.1 — sec.gov
- ALX Oncology Reports Third Quarter 2026 Financial Results — globenewswire.com
- The company's filing (ALX Oncology Holdings) — SEC filing
- ALX Oncology Holdings — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR